[
  {
    "ts": null,
    "headline": "Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the 12 Set-It-and-Forget-It Stocks to Buy Now. Amid a positive second quarter and a top executive sale, the company gains an expansion opportunity from Medtronic. Abbott Laboratories (NYSE:ABT) reported a 6.9% increase in sales for the second quarter of 2025. The earnings report, announced on July 17, 2025, also […]",
    "url": "https://finnhub.io/api/news?id=e97ca66530d4bebabf155248d6db106aa08336d7b764d792ce79cd42444863ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759354137,
      "headline": "Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale",
      "id": 136952226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the 12 Set-It-and-Forget-It Stocks to Buy Now. Amid a positive second quarter and a top executive sale, the company gains an expansion opportunity from Medtronic. Abbott Laboratories (NYSE:ABT) reported a 6.9% increase in sales for the second quarter of 2025. The earnings report, announced on July 17, 2025, also […]",
      "url": "https://finnhub.io/api/news?id=e97ca66530d4bebabf155248d6db106aa08336d7b764d792ce79cd42444863ae"
    }
  },
  {
    "ts": null,
    "headline": "Marla Beck Steps Down as CEO of Hydrafacial Owner",
    "summary": "Beck will be succeeded as president and CEO of BeautyHealth by Pedro Malha.",
    "url": "https://finnhub.io/api/news?id=0f7c502ea0d4a35f1e71111300da45447cb3edf22b709053c37dc9ce9162c6d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759331485,
      "headline": "Marla Beck Steps Down as CEO of Hydrafacial Owner",
      "id": 136947244,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Beck will be succeeded as president and CEO of BeautyHealth by Pedro Malha.",
      "url": "https://finnhub.io/api/news?id=0f7c502ea0d4a35f1e71111300da45447cb3edf22b709053c37dc9ce9162c6d6"
    }
  },
  {
    "ts": null,
    "headline": "Here are the October additions to Goldman’s ’U.S. Conviction List - Directors’ Cut",
    "summary": "Investing.com -- Goldman Sachs has updated its U.S. Conviction List – Directors’ Cut for October, adding four new stocks while removing three others.",
    "url": "https://finnhub.io/api/news?id=62d6c5de6a4752c79692abed33e4860dfbbe6689f43d8d778964a0bdd742675a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759322647,
      "headline": "Here are the October additions to Goldman’s ’U.S. Conviction List - Directors’ Cut",
      "id": 136947313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Investing.com -- Goldman Sachs has updated its U.S. Conviction List – Directors’ Cut for October, adding four new stocks while removing three others.",
      "url": "https://finnhub.io/api/news?id=62d6c5de6a4752c79692abed33e4860dfbbe6689f43d8d778964a0bdd742675a"
    }
  },
  {
    "ts": null,
    "headline": "United States Continuous Glucose Monitoring (CGM) Market Forecast 2025-2033: Focus on California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, Washington, New Jersey",
    "summary": "The United States Continuous Glucose Monitoring (CGM) Market is projected to surge from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, growing at a CAGR of 8.36% from 2025-2033. Key growth drivers include the rising prevalence of diabetes, technological advancements, enhanced insurance coverage, and increased awareness. Major players like Dexcom, Abbott, and Medtronic lead the market with user-friendly, accurate devices. The integration of CGMs is pivotal for proactive diabetes management",
    "url": "https://finnhub.io/api/news?id=778ea0f24c755b343887fce862fc24e367ddb8c6783d818bf68b842abe5b1563",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759319040,
      "headline": "United States Continuous Glucose Monitoring (CGM) Market Forecast 2025-2033: Focus on California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, Washington, New Jersey",
      "id": 136944618,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The United States Continuous Glucose Monitoring (CGM) Market is projected to surge from US$ 2.05 billion in 2024 to US$ 4.23 billion by 2033, growing at a CAGR of 8.36% from 2025-2033. Key growth drivers include the rising prevalence of diabetes, technological advancements, enhanced insurance coverage, and increased awareness. Major players like Dexcom, Abbott, and Medtronic lead the market with user-friendly, accurate devices. The integration of CGMs is pivotal for proactive diabetes management",
      "url": "https://finnhub.io/api/news?id=778ea0f24c755b343887fce862fc24e367ddb8c6783d818bf68b842abe5b1563"
    }
  }
]